Eastern Bank’s Denali Therapeutics DNLI Stock Holding History

Eastern Bank’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-282	Closed	-$5.41K	–	1076
2026 Q1	$5.41K	Hold	282	–	–	﹤0.01%	928
2025 Q4	$4.66K	Buy	+282	New	+$4.76K	﹤0.01%	966

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eastern Bank's DNLI Position: Q2 2026 in Review

Eastern Bank sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 282 shares — an estimated $5.41K sold.

Eastern Bank first reported a position in DNLI in Q4 2025 and held it in 2 quarters. The position peaked at $5.41K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Eastern Bank reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Eastern Bank sold 282 Denali Therapeutics shares in Q2 2026, an estimated $5.41K.
Eastern Bank first reported a position in Denali Therapeutics in Q4 2025 and held it in 2 quarters.
Eastern Bank's Denali Therapeutics position peaked at $5.41K in Q1 2026.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.